Advac Therapeutic LLC is structured around development of vaccines and therapeutics for the treatment of infectious diseases and cancers. with initial focus on a portfolio of small-molecule therapeutics potentially radically changing current standards of lung disease treatments. Next Generation Lung Care Pneumonia is a leading cause of death in both infant and elderly populations: patients rapidly progress to severe illness requiring hospitalization and intensive care, followed by prolonged suffering and recovery of the lung tissue. With no FDA approved therapies to stimulate regrowth of healthy lung tissue, the effort of Advac personnel is to address recovery pneumonia patients and improve odds of survival by tackling development of a novel therapeutic for the regeneration of damaged lung tissue - effectvely “mimicking” well-regulated, natural healing in the lungs.
